- Home
- TLRY vs PHVS Comparison
TLRY vs PHVS Comparison
Compare TLRY & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- PHVS
- Stock Information
- Founded
- TLRY N/A
- PHVS 2015
- Country
- TLRY Canada
- PHVS Netherlands
- Employees
- TLRY N/A
- PHVS N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- PHVS Health Care
- Exchange
- TLRY Nasdaq
- PHVS Nasdaq
- Market Cap
- TLRY 871.2M
- PHVS 894.8M
- IPO Year
- TLRY 2018
- PHVS 2021
- Fundamental
- Price
- TLRY $0.95
- PHVS $16.49
- Analyst Decision
- TLRY Hold
- PHVS Strong Buy
- Analyst Count
- TLRY 3
- PHVS 5
- Target Price
- TLRY $1.88
- PHVS $41.60
- AVG Volume (30 Days)
- TLRY 51.2M
- PHVS 39.6K
- Earning Date
- TLRY 04-08-2025
- PHVS 04-09-2025
- Dividend Yield
- TLRY N/A
- PHVS N/A
- EPS Growth
- TLRY N/A
- PHVS N/A
- EPS
- TLRY N/A
- PHVS N/A
- Revenue
- TLRY $829,216,000.00
- PHVS N/A
- Revenue This Year
- TLRY $15.63
- PHVS N/A
- Revenue Next Year
- TLRY $5.63
- PHVS N/A
- P/E Ratio
- TLRY N/A
- PHVS N/A
- Revenue Growth
- TLRY 18.38
- PHVS N/A
- 52 Week Low
- TLRY $0.83
- PHVS $15.21
- 52 Week High
- TLRY $2.97
- PHVS $28.40
- Technical
- Relative Strength Index (RSI)
- TLRY 40.67
- PHVS 36.48
- Support Level
- TLRY $0.97
- PHVS $17.01
- Resistance Level
- TLRY $1.20
- PHVS $17.94
- Average True Range (ATR)
- TLRY 0.08
- PHVS 0.71
- MACD
- TLRY -0.00
- PHVS -0.09
- Stochastic Oscillator
- TLRY 33.72
- PHVS 17.44
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.